MSDC-0160 is a prototype mTOT-modulating insulin sensitizer [1]. MSDC-0160 is a thiazolidinedione insulin sensitizer without the peroxisome proliferator¨Cactivated receptor-¦Ã (PPAR-¦Ã)-dependent side effects. Co-incubation of islets with MSDC-0160 and IGF-1 reduces the resistance of insulin-signaling pathway and preserves insulin content. MSDC-0160 at 50¦ÌM alone also prevents the loss of insulin content significantly. Besides that, treatment of MSDC-0160 increases the phosphorylation of AMPK and reduces mTOR phosphorylation. Moreover, MSDC-0160 is also found to display pro-survival effects in human islets via reducing the level of cleaved caspase-3 and increasing the expression of apoptosis-related genes such as bcl2. In addition, MSDC-0160 exerts prevention of nuclear translocation with ¦Â-catenin localized on the cell membrane or cytoplasm in human ¦Â-cells

June 21, 2017

prudect name : MSDC-0160 is a prototype mTOT-modulating insulin sensitizer [1].

MSDC-0160 is a thiazolidinedione insulin sensitizer without the peroxisome proliferator¨Cactivated receptor-¦Ã (PPAR-¦Ã)-dependent side effects. Co-incubation of islets with MSDC-0160 and IGF-1 reduces the resistance of insulin-signaling pathway and preserves insulin content. MSDC-0160 at 50¦ÌM alone also prevents the loss of insulin content significantly. Besides that, treatment of MSDC-0160 increases the phosphorylation of AMPK and reduces mTOR phosphorylation. Moreover, MSDC-0160 is also found to display pro-survival effects in human islets via reducing the level of cleaved caspase-3 and increasing the expression of apoptosis-related genes such as bcl2. In addition, MSDC-0160 exerts prevention of nuclear translocation with ¦Â-catenin localized on the cell membrane or cytoplasm in human ¦Â-cells
MSDC-0160;CAY10415

Synonyms: CAS NO: MSDC-0160Molecular Formula: C19H18N2O4SMolecular Weight: 370.42Purity: 98% minSolubility: In DMSOStorage: -20 oC


web site: www.medchemexpress.com

References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18525034